Aligos Therapeutics, Inc.ALGSEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for prevalent liver diseases and viral infections. Its core pipeline includes candidates for chronic hepatitis B, non-alcoholic steatohepatitis, and other liver-related disorders, advancing R&D to serve unmet global patient needs.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Roche Finance Ltd | 15.35% | 11.0M | — | 2023-11-07 |
| Deep Track Capital, LP | 9.99% | 7.3M | — | 2023-11-02 |
| EcoR1 Capital, LLC | 9.99% | 356.1K | flat | 2024-11-14 |
| Armistice Capital, LLC | 9.99% | 319.8K | flat | 2024-11-14 |
| Adage Capital Management, L.P. | 7.12% | 218.8K | — | 2024-11-12 |
| Lawrence M. Blatt, Ph.D. | 5.30% | 3.9M | — | 2023-11-06 |
| Baker Bros. Advisors LP | 4.99% | 3.7M | — | 2024-02-14 |
| Alyeska Investment Group, L.P. | 4.80% | 146.5K | ▼ -5.19pp | 2024-11-14 |
| HHLR Advisors, Ltd. | 4.00% | 125.1K | ▼ -4.20pp | 2024-11-14 |
| ICS Opportunities II LLC | 4.00% | 123.9K | — | 2024-09-12 |
| Vivo Capital Fund VIII, L.P. | 3.50% | 124.7K | — | 2024-11-14 |
| NOS. of Above Persons | 3.00% | 2.2M | — | 2024-02-14 |
| Versant Venture Capital VI, L.P. | 1.90% | 1.5M | — | 2024-02-08 |